<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                                                                                 British Journal Cancer (2010) 103, 975 &#226;&#8364;&#8220; 986 <br />                                                                                  &amp; 2010 Cancer Research UK All rights reserved 0007 &#226;&#8364;&#8220; 0920/10 <br />                                                                                  www.bjcancer.com <br />  <br />  <br />  <br />  <br /> Selective cyclooxygenase-2 silencing mediated engineered <br /> E. coli <span id='am-393' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-394' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-395' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-396' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-397' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-398' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-399' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-400' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-401' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-402' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-403' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-404' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-405' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-406' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-407' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-408' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-409' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-410' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-411' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-412' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-413' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-414' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-415' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-416' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-417' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-418' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-419' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-420' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-421' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-422' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-423' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-424' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-425' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-426' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-427' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-428' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-429' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-430' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-431' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-432' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-433' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-434' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-435' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-436' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-437' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-438' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-439' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-440' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-441' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-442' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-443' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-444' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-445' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-446' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-447' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-448' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-449' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-450' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-451' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-452' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-453' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-454' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-455' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-456' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-457' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-458' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-459' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-460' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-461' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-462' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-463' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-464' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-465' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-466' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-467' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-468' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-469' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-470' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span>RNA interference</span> induces anti-tumour effects human <br /> colon cancer cells <br />    <br />    <br />    <br />      A Strillacci*,1, C Griffoni1, G Lazzarini1,2, MC Valerii1,2, S Di Molfetta1, F Rizzello2, M Campieri2, MP Moyer3, <br />    <br />      V Tomasi1 E Spisni*,1 <br />    <br />      1 <br />       Department Experimental Biology, University Bologna, Selmi 3, Bologna 40126, Italy; 2Department Clinical Medicine, St Orsola-Malpighi <br />    <br />      Hospital, Massarenti 9, Bologna 40138, Italy; 3INCELL Corporation, Cimarron Path 12734, San Antonio, TX 78249, USA <br />    <br />    <br />    <br />  <br />  <br />  <br />  <br />                                                                                                                                                            Translational Therapeutics <br />    <br />    <br />    <br />      BACKGROUND: Cyclooxygenase-2 (COX-2) overexpression strongly associated colorectal tumourigenesis. It been <br />    <br />      demonstrated chronic use non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br />    <br />      colorectal cancer (CRC) development progression induces severe cardiovascular effects. New strategies selective <br />    <br />      COX-2 blockade required. <br />    <br />      METHODS: We developed improved technique, based RNA interference (RNAi), gain selective COX-2 silencing CRC <br />    <br />      cells tumour-dependent expression anti-COX-2 short-hairpin RNA (shCOX-2). Anti-COX-2 shRNA-expressing vectors <br />    <br />      delivered CRC cells (in vitro) colon tissues (ex vivo) using engineered Escherichia coli strains, capable invading tumour <br />    <br />      cells (InvColi). <br />    <br />      RESULTS: A highly tumour-dependent shCOX-2 expression significant COX-2 silencing observed CRC cells following <br />    <br />      InvColi strain infection. Cyclooxygenase-2 silencing associated strong reduction proliferative invasive behaviour <br />    <br />      tumour cells. We demonstrated pivotal role COX-2 overexpression <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-5' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-10' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-13' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span>survival</span> CRC cells bacterial infection. <br />    <br />      Moreover, COX-2 silencing achieved ex vivo infecting colon tissue samples InvColi strains, leading anti-inflammatory <br />    <br />      anti-tumour effects. <br />    <br />      CONCLUSION: Our RNAi/InvColi-mediated approach offers promising tool highly selective COX-2 blockade vitro vivo. <br />    <br />      British Journal Cancer (2010) 103, 975 &#226;&#8364;&#8220; 986. doi:10.1038/sj.bjc.6605859 www.bjcancer.com <br />    <br />      Published online 17 August 2010 <br />    <br />      &amp; 2010 Cancer Research UK <br />    <br />    <br />    <br />      Keywords: COX-2; CRC; RNAi; E. coli <br />  <br />  <br /> Colorectal cancer (CRC) represents common                         80% adenocarcinomas (Eberhart et al, 1994; Sano et al, <br /> tumour humans second leading cause tumour-                         1995), overexpression strongly associated <br /> related death Western countries. In Europe, 44 00 000 new                     colon tumourigenesis vitro murine models <br /> cases 42 00 000 deaths year estimated (Ferlay et al,                 (DuBois et al, 1996; Oshima et al, 1996; Williams et al, 1996). It is <br /> 2007). The mortality rate CRC dramatically increases                     commonly accepted COX-2 contribute CRC develop- <br /> tumour cells invade primary tissue generate lymph nodal                  ment progression mechanisms involving stimula- <br /> and liver metastases. Owing high incidence mortality                  tion angiogenesis (Spisni Tomasi, 1997; In&#203;&#339;iguez et al, 2003), <br /> rate, CRC great scientific community.                     inhibition apoptosis (Tsujii DuBois, 1995) the <br />    Over decades, demonstrated                  increase cell migration/invasiveness (Yamauchi et al, 2002; <br /> chronic use non-steroidal anti-inflammatory drugs (NSAIDs),                   Strillacci et al, 2006). <br /> blocking isoforms 1 2 cyclooxygenase (COX) enzyme,                       Celecoxib rofecoxib NSAIDs marketed as <br /> confers 40 &#226;&#8364;&#8220; 50% reduction incidence CRC (Phillips et al,            selective COX-2 inhibitors used clinical <br /> 2002; Thun et al, 2002; Higuchi et al, 2003; Sandler et al, 2003).               trials test efficacy prevention and/or treatment <br /> Cyclooxygenase key enzyme metabolism arachidonate                 CRC. Unfortunately, celecoxib and, particularly, rofecoxib <br /> and regulates synthesis prostaglandins (H2, D2, E2, F2a, I2)              shown significantly increase risk adverse <br /> and tromboxanes (TXA2 TXB2), having important roles                     cardiovascular events myocardial infarction treated patients <br /> as cellular mediators. Cyclooxygenase-2 represents product                (Bresalier et al, 2005; Solomon et al, 2005). Moreover, the <br /> the Cox-2 inducible gene. It overexpressed 40% adenomas                 cardiovascular toxicity rofecoxib increased its <br />                                                                                  capability directly inhibit prostacyclin synthase activity, as <br />                                                                                  demonstrated group (Griffoni et al, 2007). Although <br /> *Correspondence: Dr A Strillacci; E-mail: antonio.strillacci@unibo.it        celecoxib marketed, rofecoxib withdrawn the <br /> Dr E Spisni; E-mail: enzo.spisni@unibo.it                                        worldwide market Merck September 2004. <br /> Received 16 April 2010; revised 21 July 2010; accepted 22 July 2010;                RNA interference (RNAi) rapidly innovative and <br /> published online 17 August 2010                                                  elective tool gene silencing post-transcriptional level. <br />                                                                  RNAi COX-2 silencing CRC cells <br />                                                                                         A Strillacci et al <br />                              976 <br />                                    RNAi-mediated gene silencing achieved using small                  informed consent participate study, approved <br />                                    interfering RNA (siRNA) short-hairpin RNA (shRNA)                   local ethical committee. <br />                                    precursor molecules. Although synthetic siRNAs introduced <br />                                    mammal cells using standard vitro transfection methods,             Plasmids <br />                                    shRNAs expressed transfecting cells plasmids (Lewis <br />                                    et al, 2002) viral-based vectors (Brummelkamp et al, 2002).            The pSUPER.retro vector (pS ), based murine stem <br />                                    Numerous advantages come shRNA-based RNAi approach:                  cell virus (MSCV) genome, purchased Oligoengine <br />                                    first, possibility obtain long-term gene silencing;          (Seattle, WA, USA). The pSUPER.retro vector expressing shCOX-2 <br />                                    second, possibility express shRNAs spatial- and/or            RNA pol III H1 promoter control (pSH1) created as <br />                                    temporal-specific manner using tissue-specific promoters               described (Strillacci et al, 2006). pSUPER.retro vectors <br />                                    introducing regulatory elements shRNA promoters.                       expressing shCOX-2 control human Cox-2 promoter <br />                                       In 2006, research group demonstrated possible        (pSCOX 2) TBE (Tcf-binding element)-based promoter (pSTBE) <br />                                    stably silence COX-2 protein CRC cell line (HT-29) using         created follows: vectors, RNA pol III transcription <br />                                    anti-COX-2 shRNA (shCOX-2). HT-29pS(shCOX 2) showed                 stop signal substituted SV40 polyA sequence between <br />                                    significant impairment malignant behaviour (Strillacci et al,          HindIII SalI restriction sites (SV40 polyA sequence was <br />                                    2006) reduced ability survive hypoxic conditions           amplified hER/pSG5 expression plasmid; forward primer: <br />                                    (Sansone et al, 2009). <span id='am-2' about='protege:TO' typeof='owl:Thing'>To</span> date, RNAi approaches used         50 -CCCAAGCTTAAATAAAGCAATAGCATCAC-30 ; reverse primer: <br />                                    efficiently silence COX-2 protein different vitro          50 -TAGAGTCGACCAGACATGATAAGAT-30 , 120 bp product); in <br />                                    models (for review, Strillacci et al, 2010).                        pSCOX 2, H1 promoter (pH1) substituted human <br />                                       Several years ago, demonstrated functional gene          Cox-2 promoter sequence (pCOX-2) ApaI BglII <br />                                    transfer bacteria mammalian cells occur.                    restriction sites (pCOX-2 sequence amplified HCA-7 <br /> Translational Therapeutics <br />  <br />  <br />  <br />  <br />                                    In particular, engineered Escherichia coli, expressing Inv            genomic DNA; forward primer: 50 -CGGGCCCTGAGCACTACCC <br />                                    HlyA genes (from Yersinia pseudotuberculosis Lysteria                 ATGATA-30 ; reverse primer: 50 -GAAGATCTCCGAGAGAA <br />                                    monocytogenes, respectively), able invade          CCTTCC-30 , 1254 bp product); pSTBE, pH1 substituted with <br />                                    release DNA host cells (Grillot-Courvalin et al, 1998). This         TBE-based promoter sequence (pTBE) ApaI BglII <br />                                    phenomenon demonstrated vivo, observed              restriction sites (the pTBE sequence amplified TOP- <br />                                    invasive E. coli deliver therapeutic genes colonic        FLASH plasmid, kindly provided Dr Hans Clevers, University <br />                                    mucosa mice (Castagliuolo et al, 2005). Similarly, successful        Hospital, Utrecht, The Netherlands; forward primer: 50 -CG <br />                                    transfer shRNA mammalian cells achieved using non-            GGCCCAAGCTATCAAAGGG-30 ; reverse primer: 50 -CGAGAT <br />                                    pathogenic E. coli transformed plasmid containing                  CTGGCGCCTCAGCTGGC-30 , 151 bp product). A comprehensive <br />                                    expression cassettes shRNA Inv/HlyA genes. In 2006,               scheme pS vectors described shown Figure 1. <br />                                    Xiang et al (2006) applied new strategy time <br />                                    (termed &#226;&#8364;&#732;trans-kingdom RNAi&#226;&#8364;&#8482;) silence b-1 catenin gene             Transfections <br />                                    (CTNNB1) human cells vitro vivo. <br />                                       In paper, effective method shCOX-         HCA-7, HT-29, HCT-116, NCM-460, HeLa HEK-293 cells were <br />                                    2-expressing vectors delivered CRC cells (in vitro)       seeded 6-well plates (B7   105 cells well) 70% confluence. <br />                                    COX-2-overexpressing colonic tissues (ex vivo), using invasive         After 24 h, cells transfected pS , pSH1, pSCOX 2 and <br />                                    E. coli strains achieve strong COX-2 silencing mediated           pSTBE vectors using Lipofectamine 2000 transfection reagent <br />                                    RNAi, coupled anti-tumour effects. This strategy prove          (Invitrogen, Carlsbad, CA, USA) according manufacturer&#226;&#8364;&#8482;s <br />                                    suitable vivo application aiming COX-2 inhibition         instructions. After 6 h incubation 371C, transfection <br />                                    CRC prevention.                                                       medium replaced 2 ml complete medium containing <br />                                                                                                              10% FCS. Cells lysed 48 h transfection real-time PCR <br />                                                                                                              western blot analyses. <br />                                    MATERIALS AND METHODS <br />                                                                                                              RNA extraction real-time PCR <br />                                    Cell lines <br />                                                                                                              Total RNA cultured cells extracted using Eurozol reagent <br />                                    Human cancer cell lines HCA-7, HT-29, HCT-116, HeLa                   (Celbio, Milan, Italy) according manufacturer&#226;&#8364;&#8482;s instructions. <br />                                    human transformed kidney cell line HEK-293 obtained                  Extracted RNA samples treated DNase I remove any <br />                                    American Type Culture Collection (Manassas, VA, USA).            genomic DNA contamination using DNA-free kit (Ambion, Austin, <br />                                    Normal human colon mucosal epithelial cell line NCM-460 (Moyer            TX, USA) reverse transcribed using RevertAid First-Strand <br />                                    et al, 1996) obtained licensing agreement INCELL         cDNA Synthesis Kit (Fermentas, Burlington, Ontario, Canada). <br />                                    Corporation (San Antonio, TX, USA). Both HT-29pS( ) HT-               Both COX-2 b-glucuronidase (GUSB) mRNAs reverse <br />                                    29pS(shCOX 2) cells previously created group,         transcribed using random hexamer primers (Fermentas). The <br />                                    described (Strillacci et al, 2006). Cell lines cultured    siCOX-2 reverse transcribed using stem-loop RT &#226;&#8364;&#8220; PCR <br />                                    371C 5% CO2 Dulbecco&#226;&#8364;&#8482;s modified Eagle&#226;&#8364;&#8482;s medium                   technique (Chen et al, 2005) using following primer: 50 -G <br />                                    (DMEM) supplemented 10% heat-inactivated fetal calf serum            TCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC <br />                                    (FCS), 2 mM L-glutamine kanamycin 100 mg ml 1. Both FCS               AAATTCC-30 . U6 RNA reverse transcribed using following <br />                                    DMEM purchased Cambrex BioWhittaker (Charles                primer: 50 -AAAATATGGAACGCTTCACG-30 . Both COX-2 mRNA <br />                                    City, IA, USA). The NCM-460 cells cultured M3 <span id='am-471' about='xsp:base' typeof='owl:Thing'>base</span>            siCOX-2 levels analysed real-time PCR using SYBR <br />                                    media obtained INCELL Corporation. All reagents           supermix (Bio-Rad, Hercules, CA, USA) iCycler (Bio- <br />                                    purchased Sigma (St Louis, MO, USA).                                 Rad) according manufacturer&#226;&#8364;&#8482;s instructions. The melting <br />                                                                                                              curve data collected check PCR specificity. Each cDNA <br />                                    Colon tissue culture                                                      sample analysed triplicate. Cyclooxygenase-2 mRNA levels <br />                                                                                                              normalised GUSB mRNA, siCOX-2 expres- <br />                                    Fresh colon biopsies collected patients affected acute       sion normalised U6 RNA levels. Relative expressions <br />                                    ulcerative colitis endoscopy immediately cultured           calculated using formula 2 2DCt values (DCt &#194;&#188; <br />                                    MegaCell RPMI-1640 medium (Sigma). Patients gave written              Ctgene Cthk). Cyclooxygenase-2 primer pair: 50 -CCTGTGCCTGAT <br />  <br />                                    British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986                                                                 &amp; 2010 Cancer Research UK <br />                                                                             RNAi COX-2 silencing CRC cells <br />                                                                            A Strillacci et al <br />                                                                                                                                                                    977 <br />                                                                                                                                                    &#226;&#8364;&#339;AAAAA&#226;&#8364;? <br />                                                                                                  RNA pol III                                      pol III stop <br />  <br />                                                                  pS&#226;&#8364;&#8220;                       pH1                           Stuffer <br />  <br />                                                                            EcoRI Apal                       BgIII                           Hind III Sall <br />  <br />                                                                                                                                        &#226;&#8364;&#339;AAAAA&#226;&#8364;? <br />                                    GFP                                                           RNA pol III                          pol III stop <br />                        PurR                  PGK <br />                                                                  pSH1                      pH1                      shCOX2 <br />              &#206;&#8221;3&#226;&#8364;&#8482;LTR <br />                                                                            EcoRI Apal                       BgIII               Hind III Sall <br />                                                     shCOX-2 <br />                              psuper.retro <br />                                                     cassette                  &#206;&#8221;pH1                         RNA pol II <br />                 Ori <br />                                                                                                                                                   SV40 <br />                                                 &#207;&#710;                pSCOX-2                      pCOX2                             shCOX2            polyA <br />  <br />                                             5&#226;&#8364;&#8482;LTR                          EcoRI Apal                                  BgIII                Hind III        Sall <br />                       AmpR <br />  <br />                                                                               &#206;&#8221;pH1       RNA pol II <br />  <br />                                                                                                                             SV40 <br />                                                                                      pTBE                 shCOX2 <br />                                                                  pSTBE                                                      polyA <br />  <br />  <br />  <br />  <br />                                                                                                                                                                          Translational Therapeutics <br />                                                                             EcoRI Apal            BgIII              Hind III        Sall <br />                                                       <br /> Figure 1 Scheme pSUPER.retro vectors. pS : original pSUPER.retro vector, H1 promoter upstream &#226;&#8364;&#732;stuffer&#226;&#8364;&#8482; sequence; pSH1: pSUPER.retro <br /> vector shCOX-2 expression controlled H1 promoter; pSCOX 2: pSUPER.retro vector shCOX-2 expression controlled human <br /> Cox-2 promoter; pSTBE: pSUPER.retro vector shCOX-2 expression controlled TBE-based promoter (carrying Tcf-binding elements). <br />  <br />  <br /> GATTGC-30 50 -CTGATGCGTGAAGTGCTG-30 (165 bp pro-                       SDS &#226;&#8364;&#8220; PAGE sample buffer boiling, 40 mg denatured proteins <br /> duct); siCOX-2 primer pair: 50 -GCAACTGCTCAACACCG-30                   separated 12% SDS &#226;&#8364;&#8220; PAGE transferred onto <br /> 50 -TGCAGGGTCCGAGGTAT-30 (56 bp product); GUSB primer                      nitrocellulose papers. After blotting, nitrocellulose papers were <br /> pair: 50 -TGGTATAAGAAGTATCAGAAGCC-30 50 -GTATC                         incubated specific antibodies. The primary antibodies used <br /> TCTCTCGCAAAAGGAAC-30 (297 bp product); U6 primer pair:                     polyclonal anti-COX-2 (Cayman Chemicals, Ann Arbor, MI, <br /> 50 -CTTCGGCAGCACATATACT-30 50 -AAAATATGGAACG                           USA) anti-b-actin (Sigma). Secondary antibodies (HRP <br /> CTTCACG-30 (99 bp product).                                                conjugated) purchased Santa Cruz Biotechnology <br />                                                                            (Santa Cruz, CA, USA). Immunolabelling visualised using <br /> InvColi strains bacterial infection                                    ECL procedure (Amersham Biosciences, Piscataway, NJ, USA). <br />                                                                            Bands quantified using densitometric image analysis software <br /> The E. coli (DH5a strain) co-transformed pGB2-O-              (Quantity One, Bio-Rad). Normalisation b-actin <br /> inv-hly plasmid (SmR &#195;&#190; , kindly provided Dr Catherine Grillot-          expression. <br /> Courvalin, Institut Pasteur, Paris) pSUPER.retro (AmpR &#195;&#190; ) <br /> vectors obtain E. coli invasive strains carrying different    Fluorescence Inv-HlyA-pTBE sequence detection <br /> shCOX-2 expression vectors (namely InvColi-pSH1, InvColi- <br /> pSCOX 2 InvColi-pSTBE) negative control (InvColi-              InvColi pSTBE-infected cells analysed 48 h infection <br /> pS ). Selection co-transformed strains based                using Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan) to <br /> streptomycin ampicillin resistance. Both HT-29 HCA-7               detect green fluorescent protein (GFP) expression. The total DNA <br /> cell lines infected InvColi strains according             infected cells extracted using phenol/chloroform procedure <br /> following procedure: cells seeded 25 cm2 flasks 50%             24 h infection, presence pGB2-O-inv-hly pSTBE <br /> confluence (B3   106 cells) antibiotic-free medium (DMEM);           plasmids confirmed standard PCR technique, followed by <br /> InvColi strains grown LB medium 371C reach                agarose gel electrophoresis analysis. Inv primer pair: 50 -GCCAA <br /> OD600 B1.00; InvColi bacteria washed twice fresh           TAAGGAGCAGGAGAC-30 50 -CCAAGGAGCCAGCCAATC-30 <br /> LB medium, re-suspended antibiotic-free DMEM added               (225 bp product); HlyA primer pair: 50 -CATTTCACATCGTC <br /> cells&#226;&#8364;&#8482; media MOI (multiplicity infection) 1:1000; 2 h    CATCTATTTG-30 50 -TTACCGTTCTCCACCATTCC-30 (100 bp <br /> of incubation 371C 5% CO2, cells washed fresh               product); pTBE sequence primer pair (see above). The PCR <br /> DMEM medium supplemented kanamycin added                   analysis performed E. coli co-transformed pGB2- <br /> flasks. Cells lysed 48 h infection western blot         O-inv-hly pSTBE plasmids (pre-heated 951C 5 min) and <br /> real-time PCR analyses. With regard colon tissue samples,               purified plasmids themselves. <br /> infection achieved immediately endoscopic resection by <br /> co-culturing biopsies InvColi-pS strains MegaCell RPMI-             Cell proliferation viability analysis <br /> 1640 medium described above. Biopsies lysed and <br /> supernatants collected 48 h infection western blot,         Both HT-29 HCA-7 cells infected InvColi strains. <br /> real-time PCR Luminex (Luminex, Austin, TX, USA) analyses.             Twenty-four hours infection (day 0), cells seeded in <br />                                                                            12-well plates (HT-29: 5   104 cells well; HCA-7: 2   104 cells <br /> Western blot                                                               well). On days 1, 2, 3, 6 8, cells trypsinised, re- <br />                                                                            suspended PBS 1   incubated 10 min 0.4% Trypan <br /> Cultured cells homogenised lysis buffer (50 mM Tris-HCl,           Blue (Sigma). Cells counted haemocytometer for <br /> pH 7.5, 2 mM EDTA, 100 mM NaCl, 1% Triton X-100, protease                  unstained (viable) stained cells. The percentage cell viability <br /> inhibitors mixture). Cell lysates incubated 1 h ice            calculated ((number unstained cells)/(number total <br /> centrifuged 12 000 g collect supernatants. After addition         cells))   100. <br />  <br /> &amp; 2010 Cancer Research UK                                                                                 British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986 <br />                                                                  RNAi COX-2 silencing CRC cells <br />                                                                                         A Strillacci et al <br />                              978 <br />                                    Cell invasion assay                                                                    RESULTS <br />                                    Invasion assay performed using Boyden chambers (New                                Selective expression siCOX-2 colon cancer cells <br />                                    Technologies Group, Milan, Italy) 8-mm pore polycarbonate <br />                                    membranes (New Technologies Group). Membranes coated                              In 2006, group demonstrated COX-2 protein be <br />                                    Matrigel (Sigma) 40-fold dilution. Assay performed                         efficiently stably downregulated constitutive expression <br />                                    using fresh DMEM supplemented 10% heat-inactivated                                siRNA targeting COX-2 mRNA (siCOX-2) (Strillacci et al, 2006). <br />                                    FCS chemoattractant agent. Forty-eight hours InvColi                      The HT-29 colon cancer cell line transduced retro- <br />                                    infection, viable HT-29 HCA-7 cells added upper                      viral vector (pSUPER.retro) containing expressing cassette <br />                                    chamber high density (3   105 cells) absence                       shCOX-2 (siCOX-2 precursor molecule). In pSUPER. <br />                                    presence phorbol 12-myristate 13-acetate (PMA) 40 nM stimula-                       retro vector, transcription shRNA sequence driven the <br />                                    tion incubated 24 h 371C. After incubation,                            human H1 promoter RNA pol III (pSH1). H1-driven transcrip- <br />                                    membranes disassembled non-invasive cells upper                        tion leads constitutive expression shRNA molecules in <br />                                    surface membrane wiped cotton swab.                                 different type transduced human cells. To improve <br />                                    The invasion index determined counting light                              selectivity siCOX-2 expression, modified expression <br />                                    microscopy number optical fields (   200 magnification)                     cassette shCOX-2 substituting promoter element. <br />                                    cells migrated lower membrane, fixing                   In particular, created pSCOX 2 vector, H1 <br />                                    staining membranes 2% Toluidine Blue.                                         promoter (pH1) substituted human Cox-2 promoter <br />                                                                                                                           (pCOX-2), pSTBE vector, pH1 substituted with <br />                                                                                                                           promoter containing TBEs (pTBEs), derived TOPFLASH <br />                                    Cytokines, chemokines, growth factors PGE2 detection                               plasmid (largely used luciferase assays). In cases, shCOX- <br /> Translational Therapeutics <br />  <br />  <br />  <br />  <br />                                    Simultaneous detection 29 extracellular factors released                         2 transcription driven RNA pol II needs polyA stop <br />                                    treated colon tissue samples performed using Luminex                               signal (which introduced pS-modified vectors, <br />                                    technology based multiplexed bead immunoassay. Before assay,                        downstream shCOX-2 sequence) (Figure 1). Using this <br />                                    cell media samples concentrated 10 times using Microcon                           approach, shCOX-2 expression dependent COX-2 <br />                                    spin devices (YM3, Millipore, Billerica, MA, USA) subse-                           Wnt/b-catenin cellular pathways, highly activated in <br />                                    quently re-suspended Bio-Plex (Bio-Rad) assay buffer. The                           CRC cells. In fact, known CRC cells overexpress the <br />                                    levels 27 cytokines, chemokines growth factors (IL-1b,                          COX-2 protein phenomenon depends transcriptional <br />                                    IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70),                   (Yamamoto et al, 1995; Duque et al, 2005; Wu et al, 2005; Kaidi <br />                                    IL-13, IL-15, IL-17, PDGF-bb, bFGF, G-CSF, GM-CSF, VEGF, TNFa,                         et al, 2006) post-transcriptional regulation (Dixon et al, 2001; <br />                                    IFNg, IP-10, Eotaxin, MCP-1, MIP-1a, MIP-1b, Rantes)                              Strillacci et al, 2009). On hand, b-catenin preferentially <br />                                    measured using human ultrasensitive cytokine 27-plex antibody                      localised plasma membrane normal colonocytes and <br />                                    bead kit (Bio-Rad). The IL-1a level measured using Milliplex                       promotes cellular adhesion, linking E-cadherin cytoskeleton. <br />                                    Map kit (Millipore), PGE2 levels measured using                       In CRC cells, consequence mutations (Morin et al, 1997) <br />                                    Luminex Prostaglandin E2 Kit (Cayman Chemicals). The assays                       and/or cellular stimuli (Brabletz et al, 2001; Castellone et al, <br />                                    performed 96-well filter plates, manufacturers&#226;&#8364;&#8482;                          2005), b-catenin frequently translocates nucleus and <br />                                    instructions. Concentration values estimated using standard                     promotes transcription genes involved cell proliferation, <br />                                    curve fifth-order polynomial equation expressed                      migration, survival, angiogenesis stemness (Brabletz et al, <br />                                    ng ml 1 log (pg ml 1), adjusting dilution factor                      2005). In nucleus, b-catenin associates transcriptional <br />                                    (Bio-Plex Manager software 5.0, Bio-Plex). The intra-assay CV,                         complex Tcf-4/Lef-1 (T-cell factor 4/lymphoid enhancer factor 1) <br />                                    including ultrafiltration immunoassay, averaged 20%.                               binds DNA TBE promoter sequences. Figure 2 shows <br />                                                                                                                           expression levels siCOX-2 different human cell <br />                                                                                                                           lines transiently transfected pS  (empty vector, negative <br />                                    Statistical analysis <br />                                                                                                                           control), pSH1, pSCOX 2 pSTBE vectors. By transfecting CRC <br />                                    Data expressed mean&#194;&#177;s.e.m. independent                                cell lines pSCOX 2 pSTBE vectors, possible gain a <br />                                    experiments. Analysis variance used assess statistical                   highly selective expression siCOX-2. In fact, HT-29 and <br />                                    significance differences. Differences considered                           HCA-7 colon cancer cells, siCOX-2 expression driven pCOX-2 <br />                                    statistically significant Po0.01.                                                   pTBE promoters resulted higher siCOX-2 <br />  <br />  <br />  <br />                                                                                                   3.5 <br />                                                                  siCOX-2/U6 relative expression <br />  <br />  <br />  <br />  <br />                                                                                                    3     HCA-7                                    * <br />                                                                                                          HT-29 <br />                                                                                                   2.5    HCT-116 <br />                                                                                                    2     NCM-460              *                       * <br />                                                                                                          HeLa                                              * <br />                                                                                                   1.5                             * <br />                                                                                                          HEK-293 <br />                                                                                                    1 <br />  <br />                                                                                                   0.5 <br />  <br />                                                                                                    0 <br />                                                                                                         pS&#226;&#8364;&#8220;        pSH1           pSCOX-2                 pSTBE <br />                                    Figure 2 Selective expression siCOX-2 CRC cells. Six human cell lines transfected pS vectors, siCOX-2 expression evaluated by <br />                                    real-time PCR (48 h transfection) normalised U6 RNA expression. For cell line, relative expression siCOX-2 refers to <br />                                    pSH1-transfected sample. Data represent mean&#194;&#177;s.e.m. independent experiments. *Po0.01. <br />  <br />  <br />                                    British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986                                                                                &amp; 2010 Cancer Research UK <br />                                                                                                                RNAi COX-2 silencing CRC cells <br />                                                                                                               A Strillacci et al <br />                                                                                                                                                                                                                979 <br /> expression driven pH1 promoter. As expected, HCT-                                               used InvColi-pSTBE. pSTBE vector, pS vectors <br /> 116 colon cancer cell line (that does express COX-2                                                   described above, carries GFP reporter gene. Both HT-29 and <br /> protein), did record significant expression siCOX-2                                               HCA-7 cells infected InvColi-pSTBE started express GFP <br /> driven pCOX-2, siCOX-2 expression driven pTBE                                                   protein 48 h infection (Figure 3A B). An B90% infection/ <br /> was slightly higher pH1. On contrary, NCM-460                                                     invasion efficiency estimated cell lines. Moreover, <br /> (normal epithelial colon cells), HeLa (human cervix carcinoma                                                 soon infection, possible detect inside cells, by <br /> cells) HEK-293 (human transformed kidney cell line) cells,                                                PCR analysis, presence Inv-HlyA pTBE sequences, <br /> siCOX-2 expression driven pCOX-2 pTBE resulted                                                   carried pGB2-O-inv-hly plasmid pSTBE vector, <br /> very low, compared pH1-driven siCOX-2 expression.                                                     respectively (Figure 3C). <br />                                                                                                                  Using InvColi-mediated RNAi approach, achieved high <br />                                                                                                               COX-2 silencing CRC cell lines. In fact, 48 h infection with <br /> InvColi infection induces COX-2 silencing CRC cell lines <br /> and significantly reduces PGE2 synthesis release                                                          invasive InvColi strains transformed shCOX-2-expressing vectors <br />                                                                                                               (InvColi-pSH1, InvColi-pSCOX 2 InvColi-pSTBE), started to <br /> In 1998, Grillot-Courvalin et al (1998) showed engineered                                             observe significant reduction COX-2 protein mRNA levels in <br /> E. coli strain, expressing heterologous Inv HlyA genes,                                               HT-29 HCA-7 cells (Figure 3D E). Interestingly, COX-2 <br /> able infect/invade mammalian cells release DNA host                                               silencing InvColi-pSTBE effective silencing <br /> cells. On basis approach, developed strategy                                              obtained InvColi-pS  (negative control) InvColi-pSH1/COX 2 <br /> induce RNAi-mediated COX-2 silencing HT-29 HCA-7                                                    bacteria. Most likely, stronger COX-2 silencing obtained with <br /> colon cancer cell lines. Bacterial LPS known induce COX-2                                               InvColi-pSTBE dependent higher siCOX-2 expression, <br /> expression human cells (Hla Neilson, 1992). Thus,                                             detected HT-29 HCA-7 cells (Figure 3D E). <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                      Translational Therapeutics <br /> tested bacterial infection CRC cells using InvColi-pS  (see                                            Silencing results highly comparable obtained after <br /> &#226;&#8364;&#732;Materials Methods&#226;&#8364;&#8482; section details InvColi-pS strains)                                            transfection pS vectors HT-29 HCA-7 cells using the <br /> at different MOIs. At MOI value 1:1000, did record                                               Lipofectamine 2000 Transfection Reagent (Invitrogen) (see Supple- <br /> any significant COX-2 overexpression presence                                                   mentary Material). We recorded significant COX-2 protein <br /> bacterial LPS (data shown). Second, provided evidence                                             silencing 5 days InvColi-pS infection (data shown). <br /> InvColi strains created laboratory able infect                                             Very interestingly, prolonged COX-2 inhibition associated a <br /> invade human CRC cells MOI 1:1000. To purpose,                                               strong impairment PGE2 production (Figure 4) and, previously <br />  <br />  <br />                                                                                                                                                                                 InvColi-pSTBE <br />                                                                                                                                         pGB2-                                      infected <br />                                                                                                                                         -inv-hly pSTBE InvColi-pSTBE                HT-29 <br />  <br />  <br />  <br />                                                                                                        249 <br />                                                                                                        200 <br />                                                                                                        140 <br />  <br />                                                                                                                                 Inv     +     &#226;&#8364;&#8220;     &#226;&#8364;&#8220;     +     &#226;&#8364;&#8220;       &#226;&#8364;&#8220;       +       &#226;&#8364;&#8220;       &#226;&#8364;&#8220; <br />                                                                                                                                HlyA     &#226;&#8364;&#8220;     +     &#226;&#8364;&#8220;     &#226;&#8364;&#8220;     +       &#226;&#8364;&#8220;       &#226;&#8364;&#8220;       +       &#226;&#8364;&#8220; <br />                                                      HT-29                        HCA-7 <br />                                                                                                                                pTBE     &#226;&#8364;&#8220;     &#226;&#8364;&#8220;     +     &#226;&#8364;&#8220;     &#226;&#8364;&#8220;       +       &#226;&#8364;&#8220;       &#226;&#8364;&#8220;       + <br />  <br />                                                       HT-29                   InvColi                                                 HCA-7                       InvColi <br />                                                                     &#226;&#8364;&#8220;      H1 <br />                                                                  pS      pS       pSCOX-2 pSTBE                                                     pS&#226;&#8364;&#8220;       pSH1 pSCOX-2 pSTBE <br />  <br />                                                 COX-2 72 kDa                                                                    COX-2 72 kDa <br />  <br />  <br />                                                  -actin 42 kDa                                                                   -actin 42 kDa <br />  <br />                                                2.5                                                                             3.5 <br />                                                                                                    * <br />                                                                  COX-2 protein                                                                    COX-2 protein                             * <br />                                                                                                                                  3 <br />                                                 2                COX-2 mRNA <br />                          Relative expression <br />  <br />  <br />  <br />  <br />                                                                                                                                                   COX-2 mRNA <br />                                                                                                          Relative expression <br />  <br />  <br />  <br />  <br />                                                                  siCOX-2               *                                       2.5                siCOX-2 <br />                                                1.5                                                                               2 <br />                                                                                                                                                                             * <br />                                                 1                                                                              1.5 <br />                                                                                  * *           * <br />                                                                                            *                                     1                                  * * <br />                                                0.5                                                                                                                                      * <br />                                                                                                                                0.5 <br />                                                                                                                                                                                     * <br />                                                 0                                                                                0 <br />                                                          pS&#226;&#8364;&#8220;      pSH1        pSCOX-2      pSTBE                                        pS&#226;&#8364;&#8220;          pSH1         pSCOX-2           pSTBE <br />  <br />                                                                         InvColi                                                                               InvColi <br />  <br /> Figure 3 InvColi-pS strains infect CRC cells induce high COX-2 silencing. GFP protein expression evaluated (A) HT-29 (B) HCA-7, <br /> 48 h InvColi- pSTBE infection (bar &#194;&#188; 30 mm). (C) PCR analysis Inv, HlyA pTBE loci performed pGB2-O-inv-hly- pSTBE-purified <br /> plasmids, lysed InvColi-pSTBE bacteria InvColi-pSTBE-infected HT-29 cells. PCR products analysed electrophoresis 2% agarose gel. <br /> COX-2 protein, COX-2 mRNA siCOX-2 levels detected (D) HT-29 (E) HCA-7 cells, 48 h InvColi strain infection, western blot <br /> and real-time PCR. COX-2 protein, COX-2 mRNA siCOX-2 expression normalised b-actin protein, GUSB (b-glucuronidase) mRNA and <br /> U6 RNA levels, respectively. Relative expression COX-2 protein, COX-2 mRNA siCOX-2 refers InvColi-pSH1-infected sample. Data represent <br /> mean&#194;&#177;s.e.m. independent experiments. *Po0.01. <br />  <br />  <br /> &amp; 2010 Cancer Research UK                                                                                                                                 British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986 <br />                                                                               RNAi COX-2 silencing CRC cells <br />                                                                                                      A Strillacci et al <br />                              980 <br />                                    demonstrated western blot analysis, strongest inhibitory effect                                                        pathway) (Sledz et al, 2003). Western blot analysis phospho- <br />                                    obtained InvColi-pSTBE infection.                                                                                     STAT-1(Tyr701) (active form) levels, normalised p85/p91 <br />                                      We evaluated COX-2 silencing induced InvColi-                                                                 STAT-1 total protein levels, showed interferon system <br />                                    RNAi result off-target effect depending                                                               response triggered high MOI values (1:100), whereas <br />                                    interferon activation (in particular, Jak-STAT                                                                    infection MOI 1:1000 did effect STAT-1 <br />                                                                                                                                                                    phosphorylation (data shown). <br />  <br />  <br />                                                                    pS(&#226;&#8364;&#8220;)                                                                                           COX-2 silencing mediated RNAi InvColi <br />                                                                                                                                                                    infection impairs proliferation, survival and <br />                                                                    pS(H1)                                 HCA-7 <br />                                                                                                                                                                    invasiveness CRC cells <br />                                                       16           pS(COX2) <br />                                                                                                                                                                    As demonstrated effective COX-2 silencing CRC cells <br />                                                       14           pS(TBE)                                                                                         mediated InvColi-pS strains, investigated <br />                                                                                                                                                                    <span id='am-159' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-160' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-175' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-178' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-186' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-194' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-206' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-214' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-223' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-227' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-234' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span>phenotype</span> infected cells. Figure 5 shows data regarding <br />                                                       12                                                                                                           proliferation viability COX-2-silenced HT-29 (Figure 5A <br />                                                                                                                                                                    B) HCA-7 (Figure 5C D) cells results high <br />                                      PGE2 (ng ml&#226;&#8364;&#8220;1) <br />  <br />  <br />  <br />  <br />                                                       10                                                                                                           accordance cell lines. InvColi-pSCOX 2 and, particular, <br />                                                                                                                                                                    InvColi-pSTBE infection induced significant reduction CRC cell <br />                                                       8                                                                                          * <br />                                                                                                            *                                                       proliferation viability, despite InvColi-pSH1 infection led <br />                                                                *                                                              *                                    slight reduction. As COX-2 overexpression involved <br />                                                       6                         * <br />                                                                                                                                                                    malignant behaviour invasiveness CRC cells, we <br /> Translational Therapeutics <br />  <br />  <br />  <br />  <br />                                                                                    *                           *                   *                 * <br />                                                                                                                                                                    analysed effect specific COX-2 silencing mediated by <br />                                                       4 <br />                                                                                                                                                                    InvColi-RNAi HT-29 HCA-7 cells performing cell <br />                                                                                                                *                  *                  *             invasion assay, 48 h InvColi infection. The invasion index <br />                                                       2 <br />                                                                                                                                                                    cell lines significantly reduced COX-2 silen- <br />                                                       0                                                                                                            cing (Figure 6A B). Although HT-29 did record <br />                                                            1               2                               3                  4                  5                 significant difference effectiveness of <br />                                                                                                           Days                                                     InvColi-pSH1, InvColi-pSCOX 2 InvColi-pSTBE, HCA-7 <br />                                                                                                                                                                    InvColi-pSCOX 2 InvColi-pSTBE, infection induced stronger <br />                                    Figure 4 Effect COX-2 silencing mediated InvColi-pS PGE2                                                               reduction invasion index respect InvColi-pSH1. The <br />                                    production release. Levels PGE2 quantified conditioned                                                           impairment invasive behaviour CRC cells RNAi- <br />                                    media derived InvColi-pS-infected HCA-7 cells, 5 days after <br />                                    infection. (E): cells infected InvColi-pS ; (&#226;&#8364;&#8482;): cells infected                                                       mediated COX-2 silencing confirmed stimulation <br />                                    InvColi-pSH1; (m): cells infected InvColi-pSCOX 2; (K): cells infected                                                PMA, known induce COX-2 expression (Crofford <br />                                    InvColi-pSTBE. Analysis carried Luminex-based multiplexed bead                                                     et al, 1994) promote cancer cell invasion (Han et al, 2000) <br />                                    immunoassay. Concentration values expressed ng ml 1 represent                                                        (Figure 6A B). These findings line pre- <br />                                    mean&#194;&#177;CV independent measurements, normalised considering                                                           vious work demonstrated stable COX-2 <br />                                    total protein extracted tissue sample. *Po0.01.                                                                downregulation HT-29 cells, mediated pH1-driven shCOX-2 <br />  <br />  <br />                                                                                                                                   HT-29                                                               HT-29 <br />                                                                                                     450                                                                          100 <br />                                                                                                     400             pS(&#226;&#8364;&#8220;)                                                         90 <br />                                                                             Cell number (x103) <br />  <br />  <br />  <br />  <br />                                                                                                     350             pS(H1) <br />                                                                                                                                                              *                    80 <br />                                                                                                                                                                  Viability (%) <br />  <br />  <br />  <br />  <br />                                                                                                     300             pS(COX2)                                                                      *                  *               * <br />                                                                                                                                                                                                   *       *                  * <br />                                                                                                     250             pS(TBE)                                                       70                                                 * <br />                                                                                                                                                              *                                            *          * <br />                                                                                                     200                                                                           60                                         * <br />                                                                                                                                                      *       *                             pS(&#226;&#8364;&#8220;)                     * <br />                                                                                                     150                                                                                    pS(H1)                            * <br />                                                                                                                                                                                   50 <br />                                                                                                     100                                              *                                     pS(COX2) <br />                                                                                                                                              *       *                            40 <br />                                                                                                      50                                                                                    pS(TBE) <br />                                                                                                                                              * <br />                                                                                                       0                                                                           30 <br />                                                                                                            0         1        2          3       6       8                             0      1       2          3       6       8 <br />                                                                                                                                   Days                                                                    Days <br />                                                                                                                                   HCA-7                                                               HCA-7 <br />                                                                                                     110                                                                          100 <br />                                                                                                     100            pS(&#226;&#8364;&#8220;) <br />                                                                                                                                                                                  90 <br />                                                                                                      90            pS(H1) <br />                                                                                Cell number (x103) <br />  <br />  <br />  <br />  <br />                                                                                                                    pS(COX2)                                                      80 <br />                                                                                                      80                                                                                        *          * <br />                                                                                                                                                                  Viability (%) <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                      *       * <br />                                                                                                      70            pS(TBE)                                                       70 <br />                                                                                                                                                                                               *           * <br />                                                                                                      60                                                      *                   60                                              * <br />                                                                                                                                                                                                       *              * <br />                                                                                                      50                                                      *                             pS(&#226;&#8364;&#8220;)                     *       *    * <br />                                                                                                                                                      *                           50 <br />                                                                                                      40                                   *                                                pS(H1)                            * <br />                                                                                                                                   *       *                                      40 <br />                                                                                                      30                                              *                                     pS(COX2) <br />                                                                                                      20                           *                                              30        pS(TBE) <br />                                                                                                      10                                                                          20 <br />                                                                                                            0         1        2          3       6       8                             0     1        2          3       6       8 <br />                                                                                                                                   Days                                                                    Days <br />  <br />                                    Figure 5 Effect COX-2 silencing mediated InvColi-pS CRC cell proliferation viability. Cell number cell viability evaluated (A, B) <br />                                    infected HT-29 (C, D) HCA-7 cells, respectively. (E): cells infected InvColi-pS ; (&#226;&#8364;&#8482;): cells infected InvColi-pSH1; (m): cells infected with <br />                                    InvColi-pSCOX 2; (K): cells infected InvColi-pSTBE. Viability evaluated using Trypan Blue exclusion assay quantified ((number of <br />                                    unstained cells)/(number total cells))   100. Data represent mean&#194;&#177;s.e.m. independent experiments. *Po0.01. <br />  <br />  <br />                                    British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986                                                                                                                                                    &amp; 2010 Cancer Research UK <br />                                                                                                                        RNAi COX-2 silencing CRC cells <br />                                                                                                                       A Strillacci et al <br />                                                                                                                                                                                                            981 <br />                                                                              HT-29                                                                HCA-7 <br />                                                         2.25                                                                       2 <br />                                                           2                                                                      1.75                             PMA &#226;&#8364;&#8220; <br />  <br />  <br />  <br />  <br />                               Relative invasion index <br />  <br />  <br />  <br />  <br />                                                                                                        Relative invasion index <br />                                                                                            PMA &#226;&#8364;&#8220; <br />                                                         1.75                                                                      1.5                             PMA + <br />                                                                                            PMA + <br />                                                          1.5 <br />                                                                                                                                  1.25 <br />                                                         1.25 <br />                                                                                                                                    1              * <br />                                                           1              * <br />                                                                                                                                  0.75 <br />                                                         0.75                           *                                                      * <br />                                                                                                    *                                                          * <br />                                                          0.5                       *                                              0.5 <br />                                                                      *                        *                                                                               * <br />                                                                                                                                  0.25                     *               * <br />                                                         0.25 <br />                                                           0                                                                        0 <br />                                                                pS&#226;&#8364;&#8220;   pSH1      pSCOX-2       pSTBE                                      pS&#226;&#8364;&#8220;   pSH1      pSCOX-2       pSTBE <br />  <br />                                                                          InvColi                                                                  InvColi <br />  <br /> Figure 6 Effect COX-2 silencing mediated InvColi-pS CRC cell invasiveness. Invasion index evaluated (A) HT-29 (B) HCA-7 cells, <br /> 48 h InvColi strain infection. The invasion assay performed using Boyden chambers 8-mm polycarbonate membranes coated Matrigel <br /> (40-fold dilution). Samples tested absence (dark bars) presence (light bars) PMA 40 nM. Relative invasion index refers HT-29 and <br /> HCA-7 cells infected InvColi-pS , treated PMA. Data represent mean&#194;&#177;s.e.m. independent experiments. *Po0.01. <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                  Translational Therapeutics <br /> expression, induces significant impairment malignant                                                             analysed 48 h infection biopsies InvColi-pS <br /> behaviour HT-29 cells (Strillacci et al, 2006).                                                                    strains (MOI 1:1000, 6 h incubation). As shown Figure 9A, <br />                                                                                                                       negative controls (untreated sample sample infected with <br />                                                                                                                       InvColi-pS ) characterised COX-2 expression, ex- <br /> CRC <span id='am-81' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-82' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-83' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-84' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-85' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-109' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-122' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-129' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-142' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span>cell survival</span> bacterial infection depends                                                                   pected. A significant COX-2 protein/mRNA reduction siCOX-2 <br /> on COX-2 overexpression                                                                                               expression recorded samples infected InvColi-pSH1, <br />                                                                                                                       InvColi-pSCOX2 InvColi-pSTBE, compared negative con- <br /> It known COX-2 key role colon cancer progression                                                     trols. Very importantly, InvColi-pSTBE infection strongest <br /> and survival colon cancer cells. Recently, demonstrated                                                    effect, confirming vitro data (see above). We also <br /> a COX-2/CA-IX (carbonic anhydrase IX) interplay controls CRC                                                          evaluated effect COX-2 silencing colon tissues by <br /> cell survival hypoxic conditions (Sansone et al, 2009).                                                         analysing levels PGE2, cytokines, chemokines growth <br /> Therefore, aimed demonstrate COX-2 overexpression                                                          factors present conditioned media 48 h infection. For <br /> is required survival CRC cells infection                                                     analysis, tissue samples infected InvColi-pS  <br /> invasive E. coli strains. As previously demonstrated                                                          (negative control) InvColi-pSTBE (which showed most <br /> (Strillacci et al, 2006), COX-2 stable silencing mediated                                                          effective COX-2 silencing) taken consideration all <br /> retroviral transduction did affect proliferation survival                                                     data collected shown Figure 9B C. As expected, COX-2 <br /> of HT-29 cells. In fact, did record difference                                                      protein silencing mediated InvColi-pSTBE led strong <br /> proliferation rate HT-29pS( ) (negative control) HT-                                                      decrease PGE2 secretion. Moreover, media derived from <br /> 29pS(shCOX 2) (in COX-2 stably downregulated). However,                                                      InvColi-pSTBE-infected cells, significant decrease in <br /> after prolonged infection invasive InvColi-pS  (MOI 1:100,                                                     IL-1a, IL-1b, IL-6, IL-8, IL-12(p70), IL-17, PDGF-bb, bFGF, VEGF, <br /> 6 h incubation, day 0), observed significant difference cell                                                  IP-10, MCP-1 MIP-1b, observed marked increase <br /> proliferation cell viability HT-29pS( ) HT-                                                           IL-1ra, IL-2, IL-15, TNFa Eotaxin. Levels IL-4, IL-5 and <br /> 29pS(shCOX 2) cells (Figure 7A B). At MOI 1:100, bacterial                                                        IL-10 detectable. Interestingly, COX-2 silencing led a <br /> infection rapidly induced COX-2 overexpression HT-29pS( )                                                          strong decrease secretion pro-inflammatory cytokines <br /> cells (days 1 &#226;&#8364;&#8220; 4), probably higher presence LPS                                                   IL-1a/b (Liu et al, 2003; Matsuo et al, 2009), IL-6 (Becker <br /> (Hla Neilson, 1992), did observe phenomenon                                                       et al, 2005) IL-8 (Brew et al, 2000), pro-angiogenic <br /> in HT-29pS(shCOX 2) cells (Figure 7C). The lack high COX-2                                                         growth factors PDGF-bb (Hsu et al, 1995), bFGF (Galzie <br /> protein levels infected HT-29pS(shCOX 2) cells led significant                                                et al, 1997) VEGF (Takahashi et al, 1995). Furthermore, there <br /> reduction cell proliferation viability. To confirm                                                 increased secretion anti-inflammatory cytokines, <br /> important role COX-2 protein CRC cell survival,                                                          IL-1ra (Konishi et al, 2005), cytokines anti- <br /> performed InvColi-pS infection HCT-116 cells, CRC cell line                                                      tumour effect, IL-2 (Caporale et al, 2007) IL-15 (Zhang <br /> not expressing COX-2 protein. As expected, COX-2 protein                                                      et al, 2009). Similarly, TNFa increased secretion exert an <br /> mRNA levels detectable HCT-116 cells 6 h                                                            anti-tumour effect colon cells, role CRC still <br /> infection InvColi-pS strains MOI 1:100 (data shown).                                                      controversial (Koshiji et al, 1998; Popivanova et al, 2008). Thus, by <br /> Importantly, absence COX-2 overexpression infected                                                          global analysis ex vivo data, results clear InvColi- <br /> HCT-116 cells led dramatic decrease cell proliferation                                                    mediated RNAi induced COX-2 silencing exerted anti- <br /> viability (Figure 8A B), HT-29pS(shCOX 2) cells. More-                                                     inflammatory anti-tumour effect colon cells. <br /> over, infected HCT-116 cells showed reduced ability invade <br /> Matrigel-coated filters (Figure 8C). <br />                                                                                                                       DISCUSSION <br /> COX-2 silencing mediated InvColi strains colon <br /> tissue samples                                                                                                        Over decades, large body experimental evidence has <br />                                                                                                                       ascribed COX-2 enzyme important role colorectal <br /> We evaluated efficacy COX-2 silencing ex vivo using                                                            tumourigenesis. Cyclooxygenase-2 overexpressed colon <br /> InvColi-based RNAi fresh colon tissue samples. To                                                             tumour tissues (Eberhart et al, 1994; Sano et al, 1995) and <br /> purpose, samples collected patients affected acute                                                       contributes CRC progression malignancy mechan- <br /> ulcerative colitis, supposed characterised COX-2 protein                                                     isms act cell proliferation/invasion (Yamauchi et al, 2002; <br /> expression. Levels COX-2 protein, COX-2 mRNA siCOX-2                                                           Strillacci et al, 2006), apoptosis inhibition (Tsujii DuBois, <br />  <br /> &amp; 2010 Cancer Research UK                                                                                                                             British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986 <br />                                                                            RNAi COX-2 silencing CRC cells <br />                                                                                                   A Strillacci et al <br />                              982 <br />                                                                                                                    HT-29                                                                               HT-29 <br />                                                                                     350                                                                                       100 <br />                                                                                     300       pS(&#226;&#8364;&#8220;) <br />                                                                                                                                                                                   90 <br />  <br />  <br />  <br />  <br />                                                                Cell number (x103) <br />                                                                                               pS(shCOX2) <br />                                                                                     250 <br />  <br />  <br />  <br />  <br />                                                                                                                                                               Viability (%) <br />                                                                                               pS(&#226;&#8364;&#8220;) INF                                                                                                                    pS(&#226;&#8364;&#8220;) <br />                                                                                                                                                                                   80 <br />                                                                                                                                                                                                                            pS(shCOX2) <br />                                                                                     200       pS(shCOX2) INF <br />                                                                                                                                                                                                                            pS(&#226;&#8364;&#8220;) INF <br />                                                                                                                                                                                   70 <br />                                                                                     150                                                                                                            *                       pS(shCOX2) INF <br />                                                                                                                                                                                   60                                   * <br />                                                                                     100                                                                                                                        * <br />                                                                                                                                                                                                                    * <br />                                                                                     50                                                                                            50 <br />                                                                                                                                 *           *         * <br />                                                                                      0                                                                                            40 <br />                                                                                           0           1               2                 3         4                                     0       1           2      3   4 <br />                                                                                                                      Days                                                                                  Days <br />  <br />                                                                                                                                                       HT-29 InvColi-infected <br />                                                                                                                                                         Days <br />                                                                                                                                                 0 1 2 3 4 0 1 2                                 3 4 <br />                                                                                                               COX-2 72 kDa <br />  <br />                                                                                                                -actin 42 kDa <br />  <br />                                                                                                                                                  HT-29-pS&#226;&#8364;&#8220;                        HT-29-pSshCOX-2 <br /> Translational Therapeutics <br />  <br />  <br />  <br />  <br />                                                                                                                                 3.5 <br />                                                                                                                                     3                                                  pS(&#226;&#8364;&#8220;) INF <br />                                                                                                           relative expression <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                        pS(shCOX2) INF <br />                                                                                                              COX-2/ -actin <br />  <br />  <br />  <br />  <br />                                                                                                                                 2.5 <br />                                                                                                                                     2 <br />                                                                                                                                 1.5 <br />                                                                                                                                                           * <br />                                                                                                                                     1                                         * <br />                                                                                                                                 0.5         *                                               * <br />                                                                                                                                                                                                            * <br />                                                                                                                                     0 <br />                                                                                                                                         0          1           2                        3              4 <br />                                                                                                                                                               Days <br />  <br />                                    Figure 7 HT-29 cell survival bacterial infection depends COX-2 overexpression. (A) Cell number, (B) cell viability (C) COX-2 protein <br />                                    expression evaluated HT-29pS( ) HT-29pS(shCOX 2) cells infected InvColi-pS  (MOI 1:100), comparison control cells (not infected). <br />                                    See &#226;&#8364;&#732;Materials Methods&#226;&#8364;&#8482; section details cell lines. (E) HT-29pS( ) cells, transduced pS( ) negative control vector; (&#226;&#8364;&#8482;) HT-29pS(shCOX 2) <br />                                    cells, transduced pS(shCOX 2) vector stably silenced COX-2 protein; (m): HT-29pS( ) INF cells, transduced pS( ) negative control vector <br />                                    infected InvColi-pS ; (K): HT-29pS(shCOX 2) INF cells, transduced pS(shCOX 2) vector infected InvColi-pS . Viability detected <br />                                    using Trypan Blue exclusion assay quantified ((number unstained cells)/(number total cells))   100. COX-2 protein expression <br />                                    evaluated western blot normalised b-actin protein. COX-2 relative expression refers infected HT-29pS( ) sample, day 0. Data <br />                                    represent mean&#194;&#177;s.e.m. independent experiments. *Po0.01. <br />  <br />  <br />  <br />                                    1995) tumour angiogenesis (Spisni Tomasi, 1997; In&#203;&#339;iguez                                                                   (pSUPER.retro, pS). These bacteria able infect/invade <br />                                    et al, 2003). It demonstrated chronic use                                                                     CRC cells release DNA contents, leading strong <br />                                    NSAIDs, inhibitors COX activity, reduces CRC incidence                                                                       COX-2 silencing. <br />                                    treated patients (Phillips et al, 2002; Thun et al, 2002; Higuchi et al,                                                              First, modified pS vector gain tumour-specific <br />                                    2003; Sandler et al, 2003). Among these, &#226;&#8364;&#732;coxibs&#226;&#8364;&#8482;                                                                        shCOX-2 expression. The basic pS vector allows constitutive <br />                                    developed marketed selective block COX-2 activity.                                                                  expression shCOX-2 (siCOX-2 precursor) every <br />                                    Celecoxib, rofecoxib, lumiracoxib etoricoxib em-                                                                     human cell line shCOX-2 transcription driven H1 <br />                                    ployed clinical trials test safety associated                                                            promoter RNA pol III (pSH1). Thus, modified this <br />                                    chronic use, data collected debated. The high incidence                                                                 expression cassette substituting H1 promoter the <br />                                    cardiovascular adverse events associated chronic use                                                                human Cox-2 promoter (in pSCOX 2) promoter sequence <br />                                    coxibs (Bresalier et al, 2005; Solomon et al, 2005) clear                                                             containing TBEs (in pSTBE), represent downstream <br />                                    pharmacological strategies, based COX-2 inhibition,                                                                  target sequences human genomic DNA Wnt/b-catenin- <br />                                    required prevention and/or treatment CRC.                                                                           activated pathway. It known Cox-2 promoter activity is <br />                                       Cyclooxygenase efficiently selectively inhibited                                                                  highly stimulated CRC cells. Many cellular stimuli contribute to <br />                                    RNAi techniques, transient long-lasting manner                                                                    activate phenomenon leads COX-2 overexpression <br />                                    (Strillacci et al, 2006). RNAi choice gene                                                                (Yamamoto et al, 1995; Dixon et al, 2001; Duque et al, 2005; <br />                                    silencing vitro despite disadvantages RNAi approaches                                                                   Wu et al, 2005; Kaidi et al, 2006; Strillacci et al, 2009). The Wnt/b- <br />                                    vivo. RNAi-based silencing molecules delivered vivo                                                                   catenin pathway highly activated CRC cells an <br />                                    intravenous injections expressed use viral-based                                                                   activation caused cellular stimuli <span id='am-237' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-238' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-239' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-240' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-245' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-247' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-248' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-250' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-254' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-255' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-257' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-259' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-260' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-268' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-270' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-272' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-278' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-286' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-289' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-291' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-292' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-296' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-298' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-301' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-302' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-306' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-307' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-310' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-312' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-314' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span>mutation</span> proteins <br />                                    systems. However, poor pharmacodynamics and/or heavy                                                                          involved pathway, APC b-catenin itself <br />                                    effects reduce use effectiveness vivo.                                                                                (Morin et al, 1997; Brabletz et al, 2001, 2005; Castellone et al, <br />                                       Hereby, provide data supporting alternative approach                                                                   2005). By use pSCOX 2 pSTBE vectors, demonstrated <br />                                    target CRC cells induce highly selective COX-2 silencing,                                                                    siCOX-2 expressed effective selective <br />                                    mediated RNAi, vitro ex vivo. In particular,                                                                        manner CRC cells. Under Cox-2 TBE-based promoter <br />                                    engineered invasive E. coli strains (InvColi) carrying siCOX-2                                                                  control, siCOX-2 expression CRC cell lines (HT-29 HCA-7) <br />                                    (siRNA sequences targeting COX-2 mRNA)-expressing vectors                                                                          higher, compared H1-driven expression. On the <br />  <br />                                    British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986                                                                                                                                                   &amp; 2010 Cancer Research UK <br />                                                                                                                                RNAi COX-2 silencing CRC cells <br />                                                                                                                               A Strillacci et al <br />                                                                                                                                                                                                                                     983 <br />                                                                             HCT-116                                                                                           HCT-116 <br />                                                   500                                                                                      120 <br />                                                   450       NI <br />                                                   400                                                                                      100 <br />  <br />  <br />  <br />  <br />                              Cell number (x103) <br />                                                             pS(&#226;&#8364;&#8220;) <br />                                                   350       pS(H1) <br />  <br />  <br />  <br />  <br />                                                                                                                            Viability (%) <br />                                                                                                                                             80 <br />                                                   300       pS(COX2) <br />                                                                                                                                                                           * <br />                                                             pS(TBE) <br />                                                   250                                                                                      60 <br />                                                   200                                                                                                    NI <br />                                                                                                                                            40            pS(&#226;&#8364;&#8220;) <br />                                                                                                                                                                                  *      *       * <br />                                                   150 <br />                                                                                                                                                          pS(H1) <br />                                                   100 <br />                                                                                                                                            20            pS(COX2) <br />                                                    50                   *                             * <br />                                                                                                               *    *                                     pS(TBE) <br />                                                     0                                                                                        0 <br />                                                         0           2                4                        6    8                                 0                2         4       6      8 <br />                                                                                     Days                                                                                       Days <br />                                                                                                                          HCT-116 <br />                                                                                                       1.2 <br />  <br />                                                                             Relative invasion index       1 <br />  <br />                                                                                                       0.8 <br />  <br />                                                                                                       0.6 <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                                           Translational Therapeutics <br />                                                                                                       0.4 <br />                                                                                                                     *              *             *                * <br />                                                                                                       0.2 <br />  <br />                                                                                                           0 <br />                                                                                                               NI   pS&#226;&#8364;&#8220;    pSH1 pSCOX-2 pSTBE <br />  <br />                                                                                                                                            InvColi <br />  <br /> Figure 8 InvColi-pS infection impairs proliferation, viability invasiveness HCT-116 cells. (A) Cell number, (B) cell viability (C) invasiveness <br /> were evaluated HCT-116 cells infected InvColi-pS strains (MOI 1:100). Viability evaluated using Trypan Blue exclusion assay quantified as <br /> ((number unstained cells)/(number total cells))   100. (E): cells infected, NI; (&#226;&#8364;&#8482;): cells infected InvColi-pS ; (m): cells infected InvColi- <br /> pSH1; (K): cells infected InvColi-pSCOX 2; (*): cells infected InvColi-pSTBE. The invasion assay performed using Boyden chambers 8-mm <br /> polycarbonate membranes coated Matrigel (40-fold dilution). Relative invasion index refers HCT-116 cells infected (NI). Data represent <br /> mean&#194;&#177;s.e.m. independent experiments. *Po0.01. <br />  <br />  <br /> contrary, siCOX-2 resulted low expression normal colon                                                             infection effect InvColi-pSH1, InvColi-pSCOX2 and <br /> epithelial cells (NCM-460) human tumour cell lines                                                                InvColi-pSTBE infection. Thus, HT-29pS(shCOX 2), the <br /> (such HeLa HEK-293).                                                                                                   biological effect HCT-116 cells dependent InvColi-pS <br />    Second, demonstrated shCOX-2-expressing vectors                                                                    infection se, siCOX-2 expression. On other <br /> (pSH1, pSCOX 2 pSTBE) efficiently delivered                                                                   hand, global effect InvColi-pS infection CRC cell lines <br /> HT-29 HCA-7 CRC cell lines infection InvColi                                                                   expressing COX-2 (HCA-7 HT-29) result COX-2 <br /> strains (MOI 1:1000), promoting strong COX-2 down-                                                                     silencing mediated RNAi, PGE2 levels reduction cellular <br /> regulation (both mRNA protein levels) mediated RNAi                                                                 stress induced bacteria infection. <br /> and prolonged reduction PGE2 levels. Most likely,                                                                      Finally, light possible vivo application, tested <br /> phenomenon led significant reduction cell proliferation,                                                            ex vivo efficacy selective COX-2 silencing mediated InvColi- <br /> viability invasiveness observed infected CRC cells. Very                                                               based RNAi. Colon tissue samples, derived patients affected by <br /> interestingly, shCOX-2 expression driven TBE promoter                                                                  acute ulcerative colitis expressing COX-2 protein, infected <br /> induced highest COX-2 silencing, resulted strong                                                               InvColi-pS strains resulted strong COX-2 <br /> impairment tumour-associated phenotype. It clear                                                                 inhibition mRNA protein levels, especially infection <br /> that, using pSTBE vector, possible gain efficacy                                                         InvColi-pSTBE. Cyclooxygenase-2 silencing associated <br /> and specificity COX-2 silencing CRC cells.                                                                             significant reduction PGE2 pro-inflammatory/ <br />    We used model demonstrate pivotal role                                                               pro-angiogenic factors (cytokines, growth factors) released colon <br /> COX-2 overexpression CRC cell survival. By infecting HT-29                                                                 InvColi-pSTBE-infected cells. Moreover, observed increased <br /> cells stably silenced COX-2 (HT-29pS(shCOX 2), previously                                                                 production factors anti-inflammatory anti-tumour effects. <br /> developed laboratory) InvColi-pS  higher MOI                                                                    In conclusion, developed RNAi-based strategy to <br /> value (1:100), observed significant reduction cell                                                                    efficiently specifically silence COX-2 protein CRC cells, <br /> proliferation survival, respect negative control                                                              vitro ex vivo. Cyclooxygenase-2 downregulation, depending <br /> (HT-29pS( ) cells). As known bacterial LPS induces                                                            InvColi-pS infection, induced strong impairment both <br /> COX-2 expression human cells and, herein, InvColi-                                                              proliferative invasive behaviour CRC cells vitro a <br /> pS  infection MOI 1:100 induces COX-2 overexpression                                                                 significant anti-inflammatory anti-tumour effect ex vivo. <br /> CRC cells, hypothesis survival CRC cells                                                             Taken together, data demonstrate feasibility RNAi- <br /> bacterial infection strictly dependent COX-2 induc-                                                               based/InvColi-driven approach COX-2 silencing aimed the <br /> tion. This observation confirmed HCT-116 cells,                                                              prevention CRC treatment inflammatory bowel <br /> CRC cell line unable express COX-2. In fact, lack COX-2                                                             diseases characterised COX-2 overexpression. Using engineered <br /> protein induction InvColi-pS strain infection led                                                                  E. coli strains non-pathogenic bacteria, siCOX-2 silencing <br /> significant impairment cell proliferation, viability invasive-                                                         locally delivered expressed colorectal tissues, thus <br /> ness HCT-116 cells. We did record differences                                                              promoting blockade COX-2 activity, supposedly deprived of <br /> four InvColi-pS strains used HCT-116 infection. InvColi-pS                                                                systemic effects. <br />  <br /> &amp; 2010 Cancer Research UK                                                                                                                                                      British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986 <br />                                                                      RNAi COX-2 silencing CRC cells <br />                                                                                             A Strillacci et al <br />                              984 <br />                                                                                                                                     InvColi <br />                                                                                                                         &#226;&#8364;&#8220; <br />                                                                                                              NC     pS          pSH1 pSCOX-2 pSTBE <br />                                                                                                                                                                                                   2 <br />                                                                                            COX-2 72 kDa <br />                                                                                                                                                                                                 1.8 <br />                                                                                                                                                                                                 1.6 <br />                                                                                             -actin 42 kDa <br />  <br />  <br />  <br />  <br />                                                                                                                                                                             PGE2 log (pg ml ) <br />                                                                                                                                                                            &#226;&#8364;&#8220;1 <br />                                                                                                                                                                                                 1.4 <br />                                                                                      1.2                                                                                                        1.2 <br />                                                                                                                         COX-2 protein <br />                                                                                                                                                                                                   1                                   * <br />                                                                                                                                                                * <br />                                                                Relative expression    1                                 COX-2 mRNA <br />                                                                                                                         siCOX-2                                                                 0.8 <br />                                                                                      0.8                                    * <br />                                                                                                                                            *                                                    0.6 <br />                                                                                      0.6                                                                                                        0.4 <br />                                                                                                                                      * *                                                        0.2 <br />                                                                                      0.4 <br />                                                                                                                         *                                                                         0 <br />                                                                                      0.2                            * <br />                                                                                                                                                        *                                                            pS&#226;&#8364;&#8220;             pSTBE <br />                                                                                                                                                    * <br />                                                                                       0 <br />                                                                                                                                                                                                                           InvColi <br />                                                                                               NC       pS&#226;&#8364;&#8220;         pSH1          pSCOX-2 pSTBE <br />  <br />                                                                                                                             InvColi <br />  <br />                                                                                                                   IL-1  <br />                                                                                                                                                * <br /> Translational Therapeutics <br />  <br />  <br />  <br />  <br />                                                                                                                   IL-1  <br />                                                                                                                                                                                                 * <br />                                                                                                                   IL-1ra <br />                                                                                                                                                            * <br />                                                                                                                     IL-2                                                                                        &#226;&#8364;&#8220; <br />                                                                                                                                                             *                                       InvColi-pS <br />                                                                                                                     IL-6                                                                            InvColi-pSTBE <br />                                                                                                                                                    * <br />                                                                                                                     IL-7 <br />                                                                                                                     IL-8 <br />                                                                                                                                                                                                       * <br />                                                                                                                     IL-9 <br />                                                                                                             IL-12(p70) <br />                                                                                                                                                                            * <br />                                                                                                                   IL-13 <br />                                                                                                                   IL-15 <br />                                                                                                                                                    * <br />                                                                                                                   IL-17 <br />                                                                                                                                            * <br />                                                                                                             PDGF-bb <br />                                                                                                                                 * <br />                                                                                                                   bFGF <br />                                                                                                                                                                        * <br />                                                                                                                G-CSF <br />                                                                                                              GM-CSF <br />                                                                                                                   VEGF <br />                                                                                                                                                                                                 * <br />                                                                                                                   TNF  <br />                                                                                                                                                            * <br />                                                                                                                    IFN  <br />                                                                                                                   IP-10 <br />                                                                                                                                                                    * <br />                                                                                                               Eotaxin                                                       * <br />                                                                                                                MCP-1 <br />                                                                                                                                                                                                             * <br />                                                                                                               MIP-1  <br />                                                                                                                MIP-1  <br />                                                                                                                                                                                            * <br />                                                                                                                Rantes <br />                                                                                                                             1                      10            100                                                 1000 <br />                                                                                                                                                                &#226;&#8364;&#8220;1 <br />                                                                                                                                                      Log (pg ml ) <br />  <br />                                    Figure 9 InvColi-pS strains infect colon tissue samples induce high COX-2 silencing associated anti-inflammatory anti-angiogenic effects. <br />                                    (A) COX-2 protein, COX-2 mRNA siCOX-2 levels analysed colon tissue samples western blot real-time PCR, 48 h InvColi strain <br />                                    infection. COX-2 protein, COX-2 mRNA siCOX-2 expression normalised b-actin protein, GUSB (b-glucuronidase) mRNA U6 RNA <br />                                    levels, respectively. Relative expression COX-2 protein COX-2 mRNA refers infected samples (negative control, NC); relative expression of <br />                                    siCOX-2 refers InvColi-pSTBE infected samples. Data represent mean&#194;&#177;s.e.m. independent experiments. *Po0.01. (B) Levels PGE2, <br />                                    (C) cytokines, chemokines growth factors quantified InvColi-pS - InvColi-pSTBE-infected colon tissues conditioned media, 48 h after <br />                                    infection, Luminex-based multiplexed bead immunoassay. Concentration values expressed log(pg ml 1) represent mean&#194;&#177;CV three <br />                                    independent measurements, normalised considering total protein extracted tissue sample. *Po0.01. <br />  <br />  <br />  <br />  <br />                                    ACKNOWLEDGEMENTS                                                                                                                plasmid Dr Hans Clevers (University Hospital, Utrecht, The <br />                                                                                                                                                                    Netherlands) providing TOPFLASH plasmid. <br />                                    This work supported grants MIUR (FIRB 2003 <br />                                    RBNE03FMCJ VT PRIN 2008MT34AP ES). We thank <br />                                    Dr Catherine Grillot-Courvalin (Unite&#194;&#180; des Agents Antibacte&#194;&#180;riens,                                                              Supplementary Information accompanies paper British <br />                                    Institut Pasteur, Paris) providing pGB2-O-inv-hly                                                                        Journal Cancer website (http://www.nature.com/bjc) <br />  <br />                                    British Journal Cancer (2010) 103(7), 975 &#226;&#8364;&#8220; 986                                                                                                                                                       &amp; 2010 Cancer Research UK <br />                                                                                  RNAi COX-2 silencing CRC cells <br />                                                                                 A Strillacci et al <br />                                                                                                                                                                   985 <br /> REFERENCES <br /> Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S,      Hla T, Neilson K (1992) Human cyclooxygenase-2 cDNA. Proc Natl Acad <br />   Neurath MF (2005) IL-6 signaling promotes tumor growth colorectal             Sci USA 89: 7384 &#226;&#8364;&#8220; 7388 <br />   cancer. Cell Cycle 4: 217 &#226;&#8364;&#8220; 220                                               Hsu S, Huang F, Friedman E (1995) Platelet-derived growth factor-B <br /> Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A,            increases colon cancer cell growth vivo paracrine effect. J Cell <br />   Kirchner T (2005) Invasion metastasis colorectal cancer:                  Physiol 165: 239 &#226;&#8364;&#8220; 245 <br />   epithelial-mesenchymal transition, mesenchymal-epithelial transition,         In&#203;&#339;iguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM (2003) <br />   stem cells beta-catenin. Cells Tissues Organs 179: 56 &#226;&#8364;&#8220; 65                   Cyclooxygenase-2: therapeutic target angiogenesis. Trends Mol Med <br /> Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA,                 9: 73 &#226;&#8364;&#8220; 78 <br />   Knuechel R, Kirchner T (2001) Variable beta-catenin expression             Kaidi A, Qualtrough D, Williams AC, Paraskeva C (2006) Direct <br />   colorectal cancers indicates tumor progression driven tumor               transcriptional up-regulation cyclooxygenase-2 hypoxia-inducible <br />   environment. Proc Natl Acad Sci USA 98: 10356 &#226;&#8364;&#8220; 10361                            factor (HIF)-1 promotes colorectal tumor cell survival enhances <br /> Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K,               HIF-1 transcriptional activity hypoxia. Cancer Res 66: 6683 &#226;&#8364;&#8220; 6691 <br />   Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA,                  Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y, Kusunoki M (2005) <br />   Adenomatous Polyp Prevention Vioxx (APPROVe) Trial Investigators              Interleukin-1 receptor antagonist inhibits expression vascular <br />   (2005) Cardiovascular events associated rofecoxib colorectal           endothelial growth factor colorectal carcinoma. Oncology 68: 138 &#226;&#8364;&#8220; 145 <br />   adenoma chemoprevention trial. N Engl J Med 352: 1092 &#226;&#8364;&#8220; 1102                  Koshiji M, Adachi Y, Sogo S, Taketani S, Oyaizu N, Than S, Inaba M, Phawa <br /> Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE (2000)            S, Hioki K, Ikehara S (1998) Apoptosis colorectal adenocarcinoma <br />   Interleukin-8 autocrine growth factor human colon carcinoma            (COLO 201) tumour necrosis factor-alpha (TNF-alpha) and/or <br />   cells vitro. Cytokine 12: 78 &#226;&#8364;&#8220; 85                                             interferon-gamma (IFN-gamma), resulting down-modulation of <br /> Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression                   Bcl-2 expression. Clin Exp Immunol 111: 211 &#226;&#8364;&#8220; 218 <br />                                                                                 Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H (2002) Efficient <br />  <br />  <br />  <br />  <br />                                                                                                                                                                         Translational Therapeutics <br />   tumorigenicity virus-mediated RNA interference. Cancer Cell 2: 243 &#226;&#8364;&#8220; 247 <br /> Caporale A, Brescia A, Galati G, Castelli M, Saputo S, Terrenato I, Cucina A,      delivery siRNA inhibition gene expression postnatal mice. <br />   Liverani A, Gasparrini M, Ciardi A, Scarpini M, Cosenza UM (2007)                Nat Genet 32: 107 &#226;&#8364;&#8220; 108 <br />   Locoregional IL-2 therapy treatment colon cancer. Cell-induced      Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, Jung YD, <br />   lesions murine model. Anticancer Res 27: 985 &#226;&#8364;&#8220; 989                          Fan F, Takeda A, Akagi M, Bar-Eli M, Gallick GE, Ellis LM (2003) <br /> Castagliuolo I, Beggiao E, Brun P, Barzon L, Goussard S, Manganelli R,             Cyclooxygenase-2 up-regulated interleukin-1 beta human colorectal <br />   Grillot-Courvalin C, Palu` G (2005) Engineered E. coli delivers therapeutic      cancer cells multiple signaling pathways. Cancer Res 63: 3632 &#226;&#8364;&#8220; 3636 <br />   genes colonic mucosa. Gene Ther 12: 1070 &#226;&#8364;&#8220; 1078                        Matsuo Y, Sawai H, Ma J, Xu D, Ochi N, Yasuda A, Takahashi H, Funahashi <br /> Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005)                H, Takeyama H (2009) IL-1alpha secreted colon cancer cells enhances <br />   Prostaglandin E2 promotes colon cancer cell growth Gs-axin-            angiogenesis: relationship IL-1alpha release tumor cells&#226;&#8364;&#8482; <br />   beta-catenin signaling axis. Science 310: 1504 &#226;&#8364;&#8220; 1510                            potential liver metastasis. J Surg Oncol 99: 361 &#226;&#8364;&#8220; 367 <br /> Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M,           Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler <br />   Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ                   KW (1997) Activation beta-catenin-Tcf signaling colon cancer by <br />   (2005) Real-time quantification microRNAs stem-loop RT-PCR.                mutations beta-catenin APC. Science 275: 1787 &#226;&#8364;&#8220; 1790 <br />   Nucleic Acids Res 33: e179                                                    Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR (1996) <br /> Crofford LJ, Wilder RL, Ristima&#194;&#168;ki AP, Sano H, Remmers EF, Epps HR,                NCM460, anormal human colon mucosal epithelial cell line. In Vitro Cell <br />   Hla T (1994) Cyclooxygenase-1 -2 expression rheumatoid synovial           Dev Biol Anim 32: 315 &#226;&#8364;&#8220; 317 <br />   tissues. Effects interleukin-1 beta, phorbol ester, corticosteroids.   Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, <br />   J Clin Invest 93: 1095 &#226;&#8364;&#8220; 1101                                                    Trzaskos JM, Evans JF, Taketo MM (1996) Suppression intestinal <br /> Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA,                polyposis Apc delta716 <span id='am-315' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-316' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-317' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-318' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-319' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-320' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-321' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-322' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-323' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-324' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-325' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-326' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-327' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-328' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-329' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-330' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-331' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-332' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-333' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-334' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-335' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-336' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-337' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-338' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-339' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-340' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-341' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-342' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-343' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-344' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-345' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-346' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-347' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-348' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-349' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-350' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-351' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-352' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-353' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-354' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-355' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-356' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-357' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-358' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-359' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-360' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-361' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-362' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-363' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-364' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-365' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-366' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-367' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-368' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-369' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-370' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-371' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-372' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-373' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-374' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-375' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-376' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-377' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-378' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-379' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-380' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-381' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-382' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-383' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-384' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-385' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-386' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-387' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-388' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-389' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-390' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-391' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-392' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span>knockout</span> mice inhibition cyclooxygen- <br />   Prescott SM (2001) Altered expression mRNA stability factor HuR           ase 2 (COX-2). Cell 87: 803 &#226;&#8364;&#8220; 809 <br />   promotes cyclooxygenase-2 expression colon cancer cells. J Clin Invest     Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, <br />   108: 1657 &#226;&#8364;&#8220; 1665                                                                 Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su <br /> DuBois RN, Radhika A, Reddy BS, Entingh AJ (1996) Increased                        LK, Sherman J, Kelloff G, Levin B, Steinbach G, FAP Study Group (2002) <br />   cyclooxygenase-2 levels carcinogen-induced rat colonic tumors.                A randomized,  <br /> </body></html>